Sex: U
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: Tested positive with Ct-Value of 25; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested positive with Ct-Value of 25) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect products included non-company products COVID-19 VACCINE NRVV AD (CHADOX1 NCOV-19) (ASTRAZENECA COVID-19 VACCINE) for an unknown indication and TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    No Medical History information was reported.   In December 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient received dose of COVID-19 VACCINE NRVV AD (CHADOX1 NCOV-19) (ASTRAZENECA COVID-19 VACCINE) (unknown route) 1 dosage form and dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. In April 2022, the patient experienced COVID-19 (Tested positive with Ct-Value of 25). At the time of the report, COVID-19 (Tested positive with Ct-Value of 25) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In April 2022, SARS-CoV-2 test: (Positive) Positive. Ct-value 25.         Concomitant medication was not reported. Patient received Moderna booster dose 4 months ago. Patient was tested positive for COVID-19. Treatment details were not reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company comment: This spontaneous case concerns of unspecified age and gender patient with no reported medical history, who experienced the unexpected, non-serious AESI of COVID-19 that occurred in context to dose of mRNA-1273 vaccine. Latency cannot be assessed since event onset date was not disclosed. It was noted that patient received a dose with COVID-19 VACCINE NRVV AD (CHADOX1 NCOV-19) and TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) after to current vaccination (Revaccination with different COVID-19 vaccine and interchange of vaccine products). SARS-CoV-2 test was Positive approximately 4 months after vaccination with mRNA-1273. The Clinical course, Concomitant medication and treatment details were not provided, and the event outcome was unknown. The co-suspects of TOZINAMERAN and COVID-19 VACCINE NRVV AD  and congoing pandemic of COVID-19 remains a confounder. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. Events seriousness was assessed as per medical judgement and available information.; Sender's Comments: This spontaneous case concerns of unspecified age and gender patient with no reported medical history, who experienced the unexpected, non-serious AESI of COVID-19 that occurred in context to dose of mRNA-1273 vaccine. Latency cannot be assessed since event onset date was not disclosed. It was noted that patient received a dose with COVID-19 VACCINE NRVV AD (CHADOX1 NCOV-19) and TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) after to current vaccination (Revaccination with different COVID-19 vaccine and interchange of vaccine products). SARS-CoV-2 test was Positive approximately 4 months after vaccination with mRNA-1273. The Clinical course, Concomitant medication and treatment details were not provided, and the event outcome was unknown. The co-suspects of TOZINAMERAN and COVID-19 VACCINE NRVV AD  and congoing pandemic of COVID-19 remains a confounder. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. Events seriousness was assessed as per medical judgement and available information.